PARP Inhibitor Breast Cancer Trials By Name
PARP Inhibitor Breast Cancer Clinical Trials Listed by Drug Name
The below studies are PARP inhibitor studies that are currently enrolling patients with breast cancer listed by drug name. For more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.
Abbott: Veliparib (ABT-888)
AstraZeneca: Olaparib (AZD-2281)
- NCT01286987: Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
- NCT01311713: Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
Clovis: Rucaparib (formerly
- NCT01482715: A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
Sanofi-Aventis: Iniparib (BSI 201)
Page updated 01/10/12
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.